Xencor Inc (NASDAQ:XNCR)
24.29 USD
-0.280 1.140%Sponsored Reports
Previous Close (in USD) | 24.57 |
---|---|
Change | -0.280 1.140% |
52 W H/L (in USD) | 27.700/16.490 |
EBITDA (in USD) | -122.195M |
PE Ratio | -- |
Volume | 197509 |
Diluted Eps TTM | -2.17 |
Total Assets (in USD) | 952.692M |
---|---|
Total Liabilities (in USD) | 283.559M |
Revenue TTM (in USD) | 162.181M |
Cash (in USD) | 53.79M |
Market Cap (in USD) | 1,442.905 M |
Revenue Per Share TTM | 2.665 |
Gross Profit TTM (in USD) | -34.984M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Xencor Inc
Employees: 280
Key Executives
Sr. No. | Name | Title | Year Born |
---|---|---|---|
1. | Dr. Bassil I. Dahiyat Ph.D. | Co-Founder, CEO, Pres & Director | 1970 |
2. | Mr. John J. Kuch | Sr. VP & CFO | 1959 |
3. | Dr. John R. Desjarlais | Sr. VP of Research & Chief Scientific Officer | 1964 |
4. | Ms. Celia E. Eckert J.D. | Sr. VP, Gen. Counsel & Corp. Sec. | 1973 |
5. | Dr. Allen S. Yang M.D., Ph.D. | Sr. VP & Chief Medical Officer | 1968 |
6. | Mr. Charles Liles | Associate Director and Head of Corp. Communications & Investor Relations | NA |
7. | Ms. Jennifer Sandoz | VP of HR | NA |
8. | Dr. Jeremy Grunstein Ph.D. | Sr. VP of Bus. Devel. | NA |
9. | Mr. Kirk Rosemark RAC | Sr. VP of Regulatory Affairs & Quality Assurance | 1965 |
10. | Dr. Bassil I. Dahiyat Ph.D. | Co-Founder, CEO, President & Director | 1970 |
Peers
Sector: Healthcare
Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
NVO
Novo Nordisk A/S |
-1.340 1.511% | 88.9 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
NONOF
Novo Nordisk A/S |
+0.750 0.862% | 87.68 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
VRTX
Vertex Pharmaceuticals Inc |
+2.910 0.718% | 401.53 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
REGN
Regeneron Pharmaceuticals Inc |
-0.660 0.092% | 712.3 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
---|---|---|---|---|---|
Income Before Tax | -54.508M | 82.631M | -69.333M | 27.187M | -70.409M |
Minority Interest | - | - | - | - | - |
Net Income | -55.181M | 82.631M | -63.539M | 26.875M | -70.409M |
Selling General Administrative | 47.489M | 38.837M | 29.689M | 24.286M | 22.472M |
Gross Profit | 164.579M | 275.111M | 122.694M | 156.7M | 40.603M |
Reconciled Depreciation | 8.799M | 7.491M | 5.794M | 4.298M | 3.251M |
Ebit | -91.272M | 36.276M | -82.591M | 9.526M | -82.621M |
Ebitda | -82.473M | 43.767M | -76.797M | 13.824M | -79.37M |
Depreciation And Amortization | 8.799M | 7.491M | 5.794M | 4.298M | 3.251M |
Operating Income | -82.473M | 43.767M | -76.797M | 9.526M | -79.37M |
Other Operating Expenses | 247.052M | 231.344M | 199.491M | 142.876M | 119.973M |
Interest Expense | -36.764M | 7.491M | 0M | 17.661M | 0.016M |
Tax Provision | 0.673M | 0M | 0M | 0.312M | 0M |
Interest Income | 4.817M | 0.849M | 7.264M | 13.619M | 9.102M |
Net Interest Income | 4.817M | 0.849M | 7.264M | 13.619M | 9.086M |
Income Tax Expense | 0.673M | -7.491M | -5.794M | 0.312M | 8.977M |
Total Revenue | 164.579M | 275.111M | 122.694M | 156.7M | 40.603M |
Total Operating Expenses | 247.052M | 231.344M | 199.491M | 142.876M | 119.973M |
Cost Of Revenue | - | - | - | 118.59M | 97.501M |
Total Other Income Expense Net | 27.965M | 38.864M | 7.464M | 17.661M | 8.961M |
Net Income From Continuing Ops | -55.181M | 82.631M | -69.333M | 26.875M | -70.409M |
Net Income Applicable To Common Shares | -55.181M | 82.631M | -69.333M | 26.875M | -70.409M |
Balance Sheet
(Currency in USD)Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
---|---|---|---|---|---|
Total Assets | 952.692M | 846.266M | 838.211M | 703.244M | 670.25M |
Intangible Assets | 18.663M | 18.5M | 16.493M | 15.977M | 14.421M |
Other Current Assets | 18.145M | 23.283M | 60.737M | 10.726M | 6.547M |
Total Liab | 283.559M | 118.77M | 104.707M | 130.8M | 77.049M |
Total Stockholder Equity | 668.796M | 727.496M | 733.504M | 572.444M | 593.201M |
Other Current Liab | 29.346M | 18.728M | 19.443M | 17.603M | 8.995M |
Common Stock | 0.611M | 0.601M | 0.595M | 0.58M | 0.569M |
Capital Stock | 0.611M | 0.601M | 0.595M | 0.58M | 0.569M |
Retained Earnings | -464.372M | -338.285M | -283.104M | -365.735M | -296.402M |
Good Will | - | - | - | - | - |
Other Assets | - | 0.613M | 5.653M | 0.212M | 0.713M |
Cash | 53.79M | 53.942M | 143.48M | 163.544M | 50.312M |
Cash And Equivalents | - | - | - | - | - |
Total Current Liabilities | 84.709M | 63.844M | 70.738M | 121.061M | 66.558M |
Current Deferred Revenue | 31.682M | 30.32M | 37.294M | 92.615M | 45.205M |
Net Debt | 29.644M | 5.692M | -109.511M | -151.916M | -39.578M |
Short Term Debt | 9.767M | 4.708M | 33.969M | 1.889M | 2.169M |
Short Long Term Debt | 6.332M | - | - | - | - |
Short Long Term Debt Total | 83.434M | 59.634M | 33.969M | 11.628M | 10.734M |
Other Stockholder Equity | 1130.929M | 1072.132M | 1017.523M | 937.525M | 887.873M |
Property Plant Equipment | - | 93.602M | 59.97M | 21.682M | 15.805M |
Total Current Assets | 623.16M | 675.342M | 424.368M | 637.672M | 558.405M |
Long Term Investments | 209.722M | 58.209M | 331.727M | 17.101M | 71.928M |
Short Term Investments | 539.935M | 569.12M | 190.627M | 439.459M | 479.47M |
Net Receivables | 11.29M | 28.997M | 66.384M | 23.943M | 22.076M |
Long Term Debt | 14.642M | - | - | - | - |
Inventory | -11.29M | - | -36.86M | - | - |
Accounts Payable | 13.914M | 10.088M | 14.001M | 8.954M | 10.189M |
Accumulated Other Comprehensive Income | 1.291M | -6.952M | -1.51M | 0.074M | 1.161M |
Non Currrent Assets Other | 119.43M | 0.613M | 0.653M | 0.212M | 0.311M |
Non Current Assets Total | 329.532M | 170.924M | 413.843M | 65.572M | 111.845M |
Capital Lease Obligations | 62.46M | 59.634M | 33.969M | 11.628M | 10.734M |
Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
---|---|---|---|---|---|
Investments | -119.725M | -29.445M | 113.959M | -39.932M | -155.629M |
Total Cashflows From Investing Activities | -119.725M | -46.249M | 100.192M | -50.97M | -164.767M |
Total Cash From Financing Activities | 5.702M | 43.038M | 18.044M | 10.662M | 254.241M |
Net Income | -55.181M | 82.631M | -69.333M | 26.875M | -70.409M |
Change In Cash | -89.538M | -20.064M | 113.232M | 24.066M | 9.718M |
Begin Period Cash Flow | 143.48M | 163.544M | 50.312M | 26.246M | 16.528M |
End Period Cash Flow | 53.942M | 143.48M | 163.544M | 50.312M | 26.246M |
Total Cash From Operating Activities | 24.485M | -16.853M | -5.004M | 64.374M | -79.756M |
Depreciation | 8.799M | 7.491M | 5.794M | 4.298M | 3.251M |
Other Cashflows From Investing Activities | 5M | -3.505M | -3.228M | -3.685M | -1.926M |
Dividends Paid | - | - | - | - | - |
Change To Inventory | - | 1.403M | -5.878M | 3.478M | -1.363M |
Sale Purchase Of Stock | 2.092M | 1.837M | 1.427M | 1.393M | 0.936M |
Other Cashflows From Financing Activities | -119.725M | 12.281M | 16.617M | 9.269M | -6.94M |
Capital Expenditures | 43.404M | 15.981M | 13.768M | 11.038M | 9.147M |
Change In Working Capital | 48.865M | -102.601M | 48.177M | 5.442M | -33.167M |
Other Non Cash Items | -26.911M | -22.379M | -21.27M | -4.092M | 0.021M |
Free Cash Flow | -18.919M | -32.834M | -18.772M | 53.336M | -88.903M |
Funds
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | PRIMECAP Odyssey Aggressive Growth | 8 months ago | 5851457 |
2. | iShares Core S&P Small-Cap ETF | 7 months ago | 4097770 |
3. | PRIMECAP Odyssey Growth | 8 months ago | 2551470 |
4. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 1885768 |
5. | SPDR® S&P Biotech ETF | 7 months ago | 1780765 |
6. | Vanguard Small Cap Index | 7 months ago | 1548289 |
7. | US Small-Cap Growth II Equity Comp | 8 months ago | 1523315 |
8. | T. Rowe Price New Horizons | 8 months ago | 1523315 |
9. | iShares Russell 2000 ETF | 7 months ago | 1343130 |
10. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 921697 |
11. | Vanguard Small Cap Growth Index Inv | 7 months ago | 874955 |
12. | T. Rowe Price Health Sciences | 8 months ago | 838413 |
13. | Vanguard US Opportunities Ins USD Acc | 8 months ago | 687780 |
14. | Fidelity Small Cap Index | 9 months ago | 588485 |
15. | Loomis Sayles Small Cap Growth Instl | 8 months ago | 557744 |
16. | SPDR® Portfolio S&P 600 Sm Cap ETF | 7 months ago | 535806 |
17. | UBS: US Equity Small Cap Growth | 11 months ago | 535397 |
18. | Vanguard Tax-Managed Small Cap Adm | 7 months ago | 470756 |
19. | T. Rowe Price Integrated US Sm Gr Eq | 8 months ago | 468800 |
20. | iShares Biotechnology ETF | 7 months ago | 439060 |
Institutions
Sr. No. | Name | Purchased On | Shares |
---|---|---|---|
1. | BlackRock Inc | 11 months ago | 11323310 |
2. | PRIMECAP Management Company | 8 months ago | 9090707 |
3. | Vanguard Group Inc | 8 months ago | 7011042 |
4. | EcoR1 Capital, LLC | 8 months ago | 5330416 |
5. | T. Rowe Price Associates, Inc. | 8 months ago | 3819656 |
6. | State Street Corporation | 11 months ago | 3326856 |
7. | FMR Inc | 11 months ago | 2562905 |
8. | Dimensional Fund Advisors, Inc. | 8 months ago | 1371448 |
9. | Geode Capital Management, LLC | 11 months ago | 1314943 |
10. | Armistice Capital, LLC | 8 months ago | 1000000 |
11. | Loomis, Sayles & Company LP | 11 months ago | 988244 |
12. | Goldman Sachs Group Inc | 11 months ago | 875800 |
13. | Millennium Management LLC | 8 months ago | 822976 |
14. | Johnson & Johnson | 11 months ago | 748062 |
15. | Morgan Stanley - Brokerage Accounts | 11 months ago | 745047 |
16. | Northern Trust Corp | 11 months ago | 718919 |
17. | Candriam Luxembourg S.C.A. | 8 months ago | 651317 |
18. | Logos Global Management LP | 8 months ago | 650000 |
19. | Two Sigma Advisers, LLC | 8 months ago | 601900 |
20. | Two Sigma Investments LLC | 8 months ago | 599513 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).